Last edition
News about "Partner Therapeutics"
FDA Grants Orphan Drug Designation to Zenocutuzumab for Rare Cholangiocarcinoma Subset
Partner Therapeutics secures Orphan Drug Designation for zenocutuzumab-zbco in NRG1 fusion-positive cholangiocarcinoma, strengthening development of targeted therapy for this aggressive rare cancer.
Partner Therapeutics | 09/02/2026 | By News Bureau | 132
PTx Leukine Gets Approval From Japan PMDA to Treat aPAP
Partner Therapeutics, Inc. has announced that its partner, Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device Agency (PMDA) for the inhaled use of Leukine.
Partner Therapeutics | 04/04/2024 | By Aishwarya | 1551
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy